stockmarketproxy
/
EXELNasdaq SEC EDGAR

EXELIXIS, INC.

Biological Products, (No Diagnostic Substances)·ALAMEDA, CA·FY end 01/01·CIK 939767
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$2.3B$2.2B$1.8B$1.6B$1.4B
Gross Profit——————
Operating Income$872.2M$604.6M$170.9M$201.5M$286.7M
Net Income$782.6M$521.3M$207.8M$182.3M$231.1M
Operating CF$884.3M$700.0M$333.3M$362.6M$400.8M
Capex$8.4M$28.4M$40.5M$27.7M$64.2M
Free Cash Flow$875.8M$671.5M$292.9M$334.9M$336.6M
Buybacks$947.5M$652.0M$550.4M——
Dividends——————
Gross Margin——————
Operating Margin37.6%27.9%9.3%12.5%20.0%
Net Margin33.7%24.0%11.4%11.3%16.1%
FCF Margin37.7%31.0%16.0%20.8%23.5%
R&D / Revenue35.6%42.0%57.0%55.4%48.3%
Effective Tax——————
Debt / Equity——————
Buybacks / FCF108.2%97.1%187.9%——

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CGON
6:1
CEO total comp
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
CGON
$12M
Net Margin
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%
CGON
—